Evidence map›Paper›PMID 36440442›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Efficient multitool/multiplex gene engineering with TALE-BE.

Alex Boyne, Ming Yang, Sylvain Pulicani, Maria Feola, Diane Tkach, Robert Hong, Aymeric Duclert, Philippe Duchateau, Alexandre Juillerat

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Abscisic Acid-Mediated Drought Tolerance inCurrent issues in molecular biology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alex BoyneCellectis Inc., New York, NY, United States.
Ming YangCellectis Inc., New York, NY, United States.
Sylvain PulicaniCellectis, Paris, France.
Maria FeolaCellectis Inc., New York, NY, United States.
Diane TkachCellectis Inc., New York, NY, United States.
Robert HongCellectis Inc., New York, NY, United States.
Aymeric DuclertCellectis, Paris, France.
Philippe DuchateauCellectis, Paris, France.
Alexandre JuilleratCellectis Inc., New York, NY, United States.
Cellectis (United States) · USEpigénétique et Destin Cellulaire · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TALE base editors are a recent addition to the genome editing toolbox. These molecular tools are fusions of a transcription activator-like effector domain (TALE), split-DddA deaminase halves, and an uracil glycosylase inhibitor (UGI) that have the distinct ability to directly edit double strand DNA, converting a cytosine (C) to a thymine (T). To dissect the editing rules of TALE-BE, we combined the screening of dozens of TALE-BE targeting nuclear genomic loci with a medium/high throughput strategy based on precise knock-in of TALE-BE target site collections into the cell genome. This latter approach allowed us to gain in depth insight of the editing rules

Indexed as

base editorscell engineeringgene editingTALEt-cells

Identifiers

PMID36440442
PMCPMC9684181
OpenAlexW4308870386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.